MTVA · MetaVia Inc.
$1.48
-0.01 (-0.67%)
At close · Aug 17
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$9.82M
Shares
6.59M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Hyung Heon Kim | President and Chief Executive Officer | $756,328 |
| Marshall H. Woodworth | Chief Financial Officer | $562,985 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marshall H. Woodworth | Chief Financial Officer | $774,699 |
| Hyung Heon Kim | President and Chief Executive Officer | $716,404 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Hyung Heon Kim | President and Chief Executive Officer | $664,055 |
| Joseph Hooker | Former Interim President and Chief Executive Officer | $432,000 |
| Marshall H. Woodworth | Chief Financial Officer | $154,500 |
| Gil Price | Former President and Chief Executive Officer | $116,807 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gil Price | Former President and Chief Executive Officer | $501,579 |
| Hyung Heon Kim | President and Chief Executive Officer | $60,880 |
| Joseph Hooker | Former Interim President and Chief Executive Officer | — |
| Marshall H. Woodworth | Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gil Price | Former President and Chief Executive Officer | $920,276 |
| Ben Gil Price | President, and Chief Executive Officer | $920,276 |
| Richard Kang | Former President and Chief Executive Officer | $551,449 |
| Akash Bakshi | Former Chief Operating Officer | $375,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Richard Kang | Former President and Chief Executive Officer | $427,308 |
| Dr. Mark Versavel | Former Chief Medical Officer | $357,000 |
| Nicola Shannon | Former Vice President, Clinical Operations | $334,250 |
| Ben Gil Price | President, and Chief Executive Officer | — |
| Gil Price | President, and Chief Executive Officer | — |
| Akash Bakshi | Former Chief Operating Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Nicola Shannon | Former Vice President, Clinical Operations | $66,250 |
| Dr. Mark Versavel | Former Chief Medical Officer | — |
| Richard Kang | President, Chief Executive Officer, Interim Chief Financial Officer, Secretary and Treasurer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James P. Tursi, M.D. | Class I director | Appointed | 2026-06-08 |
| D. Gordon Strickland | Class I director | Appointed | 2026-06-08 |
| Hyung Heon Kim | Class II director | Appointed | 2024-06-07 |
| Andrew Koven | Class II director | Appointed | 2024-06-07 |
| Jason L. Groves | Class II director | Appointed | 2024-06-07 |
| Marshall H. Woodworth | Principal Accounting Officer | Appointed | 2024-03-04 |
| Marshall H. Woodworth | Principal Financial Officer | Appointed | 2024-03-04 |
| Marshall H. Woodworth | Chief Financial Officer | Appointed | 2024-03-04 |
| James P. Tursi, M.D. | member of the Nominating and Corporate Governance Committee | Appointed | 2023-11-06 |
| James P. Tursi, M.D. | Class I director | Appointed | 2023-11-06 |
| Marshall H. Woodworth | Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2023-10-30 |
| Na Yeon (Irene) Kim | Board of Directors | Resigned | 2023-09-19 |
| Hyung Heon Kim | Chief Executive Officer and President | Appointed | 2023-08-14 |
| Joseph Hooker | Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Of | Terminated | 2023-08-14 |
| Hyung Heon Kim | Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2023-08-14 |
| Mark A. Glickman | Class III director | Appointed | 2023-05-12 |
| Joseph Hooker | Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Of | Appointed | 2023-01-18 |
| Gil Price, M.D. | Chief Executive Officer and President | Resigned | 2023-01-18 |
| D. Gordon Strickland | Class I director | Appointed | 2022-01-28 |
| Douglas J. Swirsky | Board of Directors | Resigned | 2022-01-14 |
| Gil Price | President and Chief Executive Officer | Appointed | 2021-11-04 |
| Gil Price | Chief Medical Officer | Appointed | 2021-11-04 |
| Richard Kang | Chief Executive Officer and President | Resigned | 2021-11-04 |
| Richard Kang, Ph.D. | Chief Executive Officer and President | Resigned | 2021-11-04 |
Key facts
CIK
1638287
CUSIP
64132R503
13F (30d)
17 filings
17 filers
Visit website
Investor relations